Publication date: Jun 18, 2019
Open-label, single-arm multi-center, Phase Ia study to evaluate the safety, optimum dosage, efficacy, survival, Biomarker changes, and immunological responses of DV-1 #45AZ5 in patients with unresectable melanoma who are progressing on standard-of-care therapies. This study will be undertaken in both male and female adult patients with unresectable Stage III and Stage IV melanoma. Patients must have at least one (1) tumor mass available for injection of DV-1 #45AZ5.
- MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
- PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
- Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
- Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma